We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Phynova | LSE:PYN | London | Ordinary Share | GB00B0YBCM49 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.375 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMPYN
RNS Number : 6861O
Phynova Group PLC
11 March 2009
11 March 2009
Phynova Group plc
("Phynova" or the "Company")
Availability of Report & Accounts
The Company announces that the report and accounts for the year ended 30
September 2008 has now been posted to shareholders and is available from the
Company's website www.phynova.com.
For further information, please contact:
+------------------------------------------------------+-------------------------+
| Phynova Group plc | Tel: 01993 880700 |
| John Pool (Executive Chairman) | |
| Tony Mills (CEO Phynova Limited) | |
| Robert Miller (CEO Phynova China Limited) | |
| | |
+------------------------------------------------------+-------------------------+
| John East & Partners Limited | Tel: 020 7618 2200 |
| Simon Clements | |
| | |
+------------------------------------------------------+-------------------------+
| Capital MS&L | Tel: 020 7 307 5330 |
| Mary Clark/Anna Mitchell | |
| | |
+------------------------------------------------------+-------------------------+
Notes to editors:
About Phynova
Phynova (AIM: PYN) is a UK company developing new prescription pharmaceuticals
derived from plants used in Chinese medicines. The Company is focused on viral
and bacterial diseases, metabolic diseases and cancer. Phynova's lead product
for hepatitis C has now completed a Phase I/II trial in the US. Two further
products, for fatty liver disease and post-operative ileus, are targeted for
entry to the clinic and there are a further four products in preclinical
development.
For further information please visit www.phynova.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSSFMFFFSUSEID
1 Year Phynova Chart |
1 Month Phynova Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
